Roland G. Henry

Roland G. Henry

Auto-generated profile, based on publicly available information

Roland G. Henry

Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
APAnne-Katrin Pröbstel
Anne-Katrin Pröbstel
XZXiaoyuan Zhou
Xiaoyuan Zhou
RBRyan Baumann
Ryan Baumann
SWSven Wischnewski
Sven Wischnewski
MKMichael Kutza
Michael Kutza
SBSergio Baranzini
Sergio Baranzini
IgA + cells act as a systemic mediator between the gut and the central nervous system during active multiple sclerosis.

1 August 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RSRegina Schlaeger
Regina Schlaeger
NPNico Papinutto
Nico Papinutto
VPValentina Panara
Valentina Panara
CBCarolyn Bevan
Carolyn Bevan
ILIryna V. Lobach
Iryna V. Lobach
RHRoland G. Henry
Roland G. Henry

21 April 2004 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
JOJoonmi Oh
Joonmi Oh
RHRoland G. Henry
Roland G. Henry
APAndrea Pirzkall
Andrea Pirzkall
YLYing Lu
Ying Lu
XLXiaojuan Li
Xiaojuan Li
SNSarah J. Nelson
Sarah J. Nelson
Purpose: To investigate the potential value of pre‐external‐beam radiation therapy (XRT) choline‐to‐NAA (N‐acetylaspartate) index (CNI), apparent diffusion coefficient (ADC), and relative cerebral blood volume (rCBV) for predicting survival in newly diagnosed patients with glioblastoma multiforme (GBM).Materials and Methods: Twenty‐eight patients with GBM were studied using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI) and diffusion‐ and perfusion‐weighted imaging after surgery but prior to XRT. Patients were categorized on the basis of their volumes of morphologic and metabolic abnormalities (volume of CNI ≥ 2 and CNI values), normalized ADC (nADC), or rCBV values within the T1 contrast‐enhancing and T2 regions. The median survival time was compared.Results: A significantly shorter median survival time was observed for patients with a large volume of metabolic abnormality than for those with a small abnormality (12.0 and 17.1 months, respectively, P = 0.002). A similar pattern was observed for patients with a low mean nADC value compared to those with high mean nADC value within the T2 region (11.2 and 21.7 months, respectively, P = 0.004). A shorter median survival time was also observed for patients with contrast‐enhancing residual disease than for those without the presence of contrast enhancement with marginal significance.Conclusion: The pre‐XRT volume of the metabolic abnormality and the nADC value within the T2 region may be valuable in predicting outcome for patients with GBM. J. Magn. Reson. Imaging 2004;19:546–554.

22 June 2017 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
RSR.T. Shinohara
R.T. Shinohara
JOJ. Oh
J. Oh
GNGovind Nair
Govind Nair
PCPeter A Calabresi
Peter A Calabresi
CDChristos Davatzikos
Christos Davatzikos
TCthe NAIMS Cooperative
the NAIMS Cooperative
BACKGROUND AND PURPOSE: MR imaging can be used to measure structural changes in the brains of individuals with multiple sclerosis and is essential for diagnosis, longitudinal monitoring, and therapy evaluation. The North American Imaging in Multiple Sclerosis Cooperative steering committee developed a uniform high-resolution 3T MR imaging protocol relevant to the quantification of cerebral lesions and atrophy and implemented it at 7 sites across the United States. To assess intersite variability in scan data, we imaged a volunteer with relapsing-remitting MS with a scan-rescan at each site. MATERIALS AND METHODS: All imaging was acquired on Siemens scanners (4 Skyra, 2 Tim Trio, and 1 Verio). Expert segmentations were manually obtained for T1-hypointense and T2 (FLAIR) hyperintense lesions. Several automated lesion-detection and whole-brain, cortical, and deep gray matter volumetric pipelines were applied. Statistical analyses were conducted to assess variability across sites, as well as systematic biases in the volumetric measurements that were site-related. RESULTS: Systematic biases due to site differences in expert-traced lesion measurements were significant (P < .01 for both T1 and T2 lesion volumes), with site explaining >90% of the variation (range, 13.0–16.4 mL in T1 and 15.9–20.1 mL in T2) in lesion volumes. Site also explained >80% of the variation in most automated volumetric measurements. Output measures clustered according to scanner models, with similar results from the Skyra versus the other 2 units. CONCLUSIONS: Even in multicenter studies with consistent scanner field strength and manufacturer after protocol harmonization, systematic differences can lead to severe biases in volumetric analyses.

8 December 2021 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
ABAntje Bischof
Antje Bischof
NPNico Papinutto
Nico Papinutto
AKAnisha Keshavan
Anisha Keshavan
ABAnand Rajesh Bs
Anand Rajesh Bs
GKGina Kirkish
Gina Kirkish
RHRoland G. Henry
Roland G. Henry
Objective: A major challenge in multiple sclerosis (MS) research is the understanding of silent progression and Progressive MS. Using a novel method to accurately capture upper cervical cord area from legacy brain MRI scans we aimed to study the role of spinal cord and brain atrophy for silent progression and conversion to secondary progressive disease (SPMS).Methods: From a single‐center observational study, all RRMS (n = 360) and SPMS (n = 47) patients and 80 matched controls were evaluated. RRMS patient subsets who converted to SPMS (n = 54) or silently progressed (n = 159), respectively, during the 12‐year observation period were compared to clinically matched RRMS patients remaining RRMS (n = 54) or stable (n = 147), respectively. From brain MRI, we assessed the value of brain and spinal cord measures to predict silent progression and SPMS conversion.Results: Patients who developed SPMS showed faster cord atrophy rates (−2.19%/yr) at least 4 years before conversion compared to their RRMS matches (−0.88%/yr, p < 0.001). Spinal cord atrophy rates decelerated after conversion (−1.63%/yr, p = 0.010) towards those of SPMS patients from study entry (−1.04%). Each 1% faster spinal cord atrophy rate was associated with 69% (p < 0.0001) and 53% (p < 0.0001) shorter time to silent progression and SPMS conversion, respectively.Interpretation: Silent progression and conversion to secondary progressive disease are predominantly related to cervical cord atrophy. This atrophy is often present from the earliest disease stages and predicts the speed of silent progression and conversion to Progressive MS. Diagnosis of SPMS is rather a late recognition of this neurodegenerative process than a distinct disease phase. ANN NEUROL 2022;91:268–281

1 July 2016 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
NINoriko Isobe
Noriko Isobe
AKAnisha Keshavan
Anisha Keshavan
PGPierre-Antoine Gourraud
Pierre-Antoine Gourraud
AZAlyssa H. Zhu
Alyssa H. Zhu
EDEsha Datta
Esha Datta
RHRoland G. Henry
Roland G. Henry
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and, in countries populated by northern Europeans and their descendants, a leading cause of progressive neurologic dysfunction in young adults.1 A large body of data confirms a multifactorial source, and a decade of large-scale genomic screens identified more than 100 genomic regions in which variants are associated with increased susceptibility.2 The strongest genome-wide susceptibility locus maps to the major histocompatibility complex (MHC) (6p21.3) accounting for approximately 10.5% of the genetic variance underlying the risk for MS. This pivotal association also reflects the complexity of MS risk inheritance by harboring multiple statistically independent allelic and haplotypic effects3,4 including 2 specific interactions involving pairs of class II alleles: DQA1*01:01-DRB1*15:01 and DQB1*03:01-DQB1*03:02.5